Pacira BioSciences reports strong Q1 2026 results and urges shareholders to support its board nominees against activist investors.

Pacira BioSciences announced solid first quarter 2026 financial results with a 5% revenue increase to $177 million, driven by growth across its product portfolio including EXPAREL, ZILRETTA, and iovera°. The company highlighted successful execution of its 5x30 strategy aimed at long-term value creation, with stock up over 30% since its launch. Pacira is urging shareholders to vote for its highly qualified board nominees to prevent activist investor DOMA Perpetual from disrupting its strategic plan, which includes cost cuts and an immediate sale. The company remains confident in its growth trajectory and pipeline advancements with key clinical readouts expected later in 2026.